Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer

References

• Yang MJ, Chiu HH, Wang HM, Yen LC, Tsao DA, Hsiao CP, Chen YF, Wang JY, Lin SR. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol 2010; 17(2):624-33; PMID:19937133; http://dx.doi.org/10.1245/s10434-009-0831-8
   PubMed Web of Science ®Google Scholar
• Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, Chang YT, Chu KS, Lin SR, Wang JY. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2009; 15(13):4508-13; PMID:19549774; http://dx.doi.org/10.1158/1078-0432.CCR-08-3179
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Current Opin Genet Dev 2010; 20:96-9; PMID:20071161; http://dx.doi.org/10.1016/j.gde.2009.12.002
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359(17):1757-65; PMID:18946061; http://dx.doi.org/10.1056/NEJMoa0804385
   PubMed Web of Science ®Google Scholar
• Ramos FJ, Macarulla T, Capdevila J, Elez E, Tabernero J. Understanding the predictive role of K-ras for epidermal growth factor receptor-argeted therapies in colorectal cancer. Clin Colorectal Cancer 2008; 7 Suppl 2:S52-7; PMID:19064407; http://dx.doi.org/10.3816/CCC.2008.s.008
   PubMedGoogle Scholar
• Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD, Newcomb PA. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 2013; 108(8):1757-64; PMID:23511557; http://dx.doi.org/10.1038/bjc.2013.118
   PubMed Web of Science ®Google Scholar
• Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, Kraan J, Lalmahomed Z, van Galen A, de Weerd V, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 2013; 133(1):130-41; PMID:23233388; http://dx.doi.org/10.1002/ijc.27987
   PubMed Web of Science ®Google Scholar
• Okada.K, Kimura T, Mikamo H, Kasahara K, Seki M, Takakura S, Tokimatsu I, Ohmagari N,Takahashi Y, Matsumoto K, et al. Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 2014; 20(1):1-5; PMID:2448616; http://dx.doi.org/10.1016/j.jiac.2013.08.008
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11(8):753-62; PMID:20619739; http://dx.doi.org/10.1016/S1470-2045(10)70130-3
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(19):3213-21; PMID:18591556; http://dx.doi.org/10.1200/JCO.2007.15.8923
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009 Jul; 20(7):1223-9; PMID:19282466; http://dx.doi.org/10.1093/annonc/mdn786
   PubMed Web of Science ®Google Scholar
• Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist. 2012; 17(7):947-55; PMID:22643538; http://dx.doi.org/10.1634/theoncologist.2012-0048
   PubMed Web of Science ®Google Scholar
• Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Diéras V, Rolland E, Mignot L, Mathiot C, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast câncer patients. Ann Oncol. 2012; 23(3):618-24; PMID:21642515; http://dx.doi.org/10.1093/annonc/mdr263
   PubMed Web of Science ®Google Scholar
• de Albuquerque A, Kubisch I, Stölzel U, Ernst D, Boese-Landgraf J, Breier G, Stamminger G, Fersis N, Kaul S. Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med 2012; 10:222; PMID:23146106; http://dx.doi.org/10.1186/1479-5876-10-222
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Fortina P. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 369(1):93; PMID:23822789; http://dx.doi.org/10.1056/NEJMc1306040
   PubMed Web of Science ®Google Scholar
• Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, Büchler MW, Koch M, Weitz J. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010; 138(5):1714-26; PMID:20100481; http://dx.doi.org/10.1053/j.gastro.2010.01.008
   PubMed Web of Science ®Google Scholar
• Sastre J, Vidaurreta M, Gómez A, Rivera F, Massutí B, López MR, Abad A, Gallen M, Benavides M, Aranda E, et al. Spanish Cooperative Group for the Treatment of Digestive Tumors. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. Clin Colorectal Cancer 2013; 12(4):280-6; PMID:24012456; http://dx.doi.org/10.1016/j.clcc.2013.06.001
   PubMed Web of Science ®Google Scholar
• Steinert G, Schölch S, Niemietz T, Iwata N, García SA, Behrens B, Voigt A, Kloor M, Benner A, Bork U, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res 2014; 74(6):1694-704; PMID:24599131; http://dx.doi.org/10.1158/0008-5472.CAN-13-1885
   PubMed Web of Science ®Google Scholar
• Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P, Chiadini E, Passardi A, Frassineti GL, Ragazzini A, et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett 2013; 335(1):225-31; PMID:23419522; http://dx.doi.org/10.1016/j.canlet.2013.02.015
   PubMed Web of Science ®Google Scholar
• Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, Mauermann O, Izbicki JR, Pantel K, Riethdorf S. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem 2013; 59(1):252-60; PMID:23136247; http://dx.doi.org/10.1373/clinchem.2012.188557
   PubMed Web of Science ®Google Scholar
• Raimondi C, Nicolazzo C, Gradilone A, Giannini G, De Falco E, Chimenti I, Varriale E, Hauch S, Plappert L, Cortesi E, Gazzaniga P. Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer. Cancer Biol Ther 2014; 15(5):496-503; PMID:24521660; http://dx.doi.org/10.4161/cbt.28020
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486(7404):537-40; PMID:22722843
   PubMed Web of Science ®Google Scholar
• Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16(3):790-9; PMID:20103678; http://dx.doi.org/10.1158/1078-0432.CCR-09-2446
   PubMed Web of Science ®Google Scholar
• Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009; 9: 302-12; PMID:19308069; http://dx.doi.org/10.1038/nrc2627
   PubMed Web of Science ®Google Scholar
• Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005 Aug; 7(3):413-21; PMID:16049314; http://dx.doi.org/10.1016/S1525-1578(10)60571-5
   PubMed Web of Science ®Google Scholar
• Sha J, Liang G, Pan J, Xuan H, Ping P, Li D, Bo J, Liu D, Shen W, Liu W, et al. Application of pyrosequencing technique for improved detection of K-Ras mutation in formalin-fixed and paraffin-embedded prostate carcinoma tissues in Chinese patients. Clin Chim Acta. 2012; 413(19-20):1532-5; PMID:22732508; http://dx.doi.org/10.1016/j.cca.2012.06.008
   PubMed Web of Science ®Google Scholar
• Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, Capron F, Franco D, Pazzagli M, Vekemans M, et al. Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000; 156(1):57-63; PMID:10623654; http://dx.doi.org/10.1016/S0002-9440(10)64706-2
   PubMed Web of Science ®Google Scholar
• Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, et al Analysis of circulating tumor cells in patients with non-small cell lung cancer using epitelial marker-dependent and -independent approaches. J Thorac Oncol 2012; 7(2):306-15; PMID:22173704; http://dx.doi.org/10.1097/JTO.0b013e31823c5c16
   PubMed Web of Science ®Google Scholar
• Hofman V, Long E, Ilie M, Bonnetaud C, Vignaud JM, Fléjou JF, Lantuejoul S, Piaton E, Mourad N, Butori C, et al. Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology 2012; 23(1):30-8; PMID:21210876; http://dx.doi.org/10.1111/j.1365-2303.2010.00835.x
   PubMed Web of Science ®Google Scholar
• Chinen LTD, Mello CAL, Abdallah EA, Ocea LMM, Buim ME, Breve NM, Junior JLG, Fanelli, MF, Paterlini-Brechót P. Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: a window on sarcoma-cell invasion. Onco Targets Ther 2014; 7:1609-17; PMID:25258541; http://dx.doi.org/10.2147/OTT.S62349
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47; PMID:19097774; http://dx.doi.org/10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Chinen LT, de Carvalho FM, Rocha BM, Aguiar CM, Abdallah EA, Campanha D, Mingues NB, de Oliveira TB, Maciel MS, Cervantes GM, et al. Cytokeratin-based CTC counting unrelated to clinical follow up. J Thorac Dis 2013; 5(5):593-9; PMID:24255771
   PubMed Web of Science ®Google Scholar
• Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, Hughes A, Blackhall F, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer 2012; 106(3):508-16; PMID:22187035; http://dx.doi.org/10.1038/bjc.2011.545
   PubMed Web of Science ®Google Scholar
• Hofman V, Ilie M, Long E, Selva E, Bonnetaud C, Molina T, Vénissac N, Mouroux J, Vielh P, Hofman P. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay TM and the isolation by size of epithelial tumor cell method. Int J Cancer 2011c; 129:1651-60; PMID:21128227; http://dx.doi.org/10.1002/ijc.25819
   PubMed Web of Science ®Google Scholar
• Tougeron D, Cortes U, Ferru A, Villalva C, Silvain C, Tourani JM, Levillain P, Karayan-Tapon L. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemother Pharmacol 2013; 72(2):397-403; PMID:23765179; http://dx.doi.org/10.1007/s00280-013-2211-0
   PubMed Web of Science ®Google Scholar